HPV Vaccination Compared to Placebo for Treating Hard-to-Treat Skin Warts A Randomized, Double-Blind Study in Adults

What this Trial Is About

Researchers are evaluating the use of the human papillomavirus HPV vaccine for treating refractory cutaneous warts, which are common skin growths that can be painful, persistent, and difficult to treat. This randomized, double-blinded, placebo-controlled trial aims to determine if HPV vaccination can be an effective therapy for these stubborn warts, as current treatments often fail and warts can cause significant discomfort and distress. Participants will be randomly assigned to receive either the 9-valent HPV vaccine or a placebo. Injections are given as a 0.5-mL intramuscular dose at weeks 0, 4, and 20. The study includes 120 participants and follows them for 24 weeks to assess the vaccines effect on wart resolution and participants quality of life. During the trial, participants will have regular evaluations including assessments of their wart response at 4, 8, and 24 weeks after the first dose. Quality of life will be measured at multiple time points using the Skindex-16 questionnaire. Safety will be monitored throughout the study by recording any adverse events. The entire study duration for participants is 24 weeks, during which they will attend scheduled visits for injections and evaluations.

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts